{
	"@context": {
		"rdf": "http://www.w3.org/1999/02/22-rdf-syntax-ns#",
		"dct": "http://purl.org/dc/terms/",
		"owl": "http://www.w3.org/2002/07/owl#",
		"xsd": "http://www.w3.org/2001/XMLSchema#",
		"rdfs": "http://www.w3.org/2000/01/rdf-schema#",
		"@vocab": "http://ld.nice.org.uk/ns/bnf#",
		"bnf": "http://ld.nice.org.uk/ns/bnf/",
		"nicebnf": "http://ld.nice.org.uk/ns/bnf#",
		"route": "http://ld.nice.org.uk/ns/bnf/Route#",
		"patientGroup": "http://ld.nice.org.uk/ns/bnf/PatientGroup#",
		"indication": "http://ld.nice.org.uk/ns/bnf/Indication#",
		"sideEffect": "http://ld.nice.org.uk/ns/bnf/SideEffect#",
		"classification": "http://ld.nice.org.uk/ns/bnf/Classification#",
		"isLinkedFrom": {
			"@container": "@set"
		},
		"hasInteraction": {
			"@container": "@set"
		},
		"hasMessage": {
			"@container": "@set"
		},
		"hasInteractionList": {
			"@container": "@set"
		},
		"isInteractionListOf": {
			"@container": "@set"
		}
	},
	"@graph": [
		{
			"@id": "http://bnf.nice.org.uk/interaction/brentuximab-vedotin-2",
			"@type": "InteractionList",
			"hasInteraction": [
				{
					"@id": "http://bnf.nice.org.uk/interaction/brentuximab-vedotin-2#bnf_i1557280691037",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/brentuximab-vedotin-2#bnf_i1557280691037_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"brentuximab vedotin\" outputclass=\"int-heading-drug\">brentuximab vedotin</ph> and <ph otherprops=\"afatinib\" outputclass=\"int-drug\">afatinib</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  brentuximab vedotin  and  afatinib  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "1",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Afatinib</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/brentuximab-vedotin-2#bnf_i1557280691038",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/brentuximab-vedotin-2#bnf_i1557280691038_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"brentuximab vedotin\" outputclass=\"int-heading-drug\">brentuximab vedotin</ph> and <ph otherprops=\"aflibercept\" outputclass=\"int-drug\">aflibercept</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  brentuximab vedotin  and  aflibercept  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "2",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Aflibercept</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/brentuximab-vedotin-2#bnf_i1557280691039",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/brentuximab-vedotin-2#bnf_i1557280691039_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"brentuximab vedotin\" outputclass=\"int-heading-drug\">brentuximab vedotin</ph> and <ph otherprops=\"amiodarone\" outputclass=\"int-drug\">amiodarone</ph> can increase the risk of peripheral neuropathy.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  brentuximab vedotin  and  amiodarone  can increase the risk of peripheral neuropathy. \n\n"
						}
					],
					"hasOrder": "3",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Amiodarone</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/brentuximab-vedotin-2#bnf_i1557280691040",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/brentuximab-vedotin-2#bnf_i1557280691040_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"brentuximab vedotin\" outputclass=\"int-heading-drug\">brentuximab vedotin</ph> and <ph otherprops=\"amsacrine\" outputclass=\"int-drug\">amsacrine</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  brentuximab vedotin  and  amsacrine  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "4",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Amsacrine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/brentuximab-vedotin-2#bnf_i1557280691041",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/brentuximab-vedotin-2#bnf_i1557280691041_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"brentuximab vedotin\" outputclass=\"int-heading-drug\">brentuximab vedotin</ph> and <ph otherprops=\"anakinra\" outputclass=\"int-drug\">anakinra</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  brentuximab vedotin  and  anakinra  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "5",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Anakinra</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/brentuximab-vedotin-2#bnf_i1557280691042",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/brentuximab-vedotin-2#bnf_i1557280691042_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"brentuximab vedotin\" outputclass=\"int-heading-drug\">brentuximab vedotin</ph> and <ph otherprops=\"arsenic trioxide\" outputclass=\"int-drug\">arsenic trioxide</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  brentuximab vedotin  and  arsenic trioxide  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "6",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Arsenic trioxide</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/brentuximab-vedotin-2#bnf_i1557280691043",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/brentuximab-vedotin-2#bnf_i1557280691043_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"brentuximab vedotin\" outputclass=\"int-heading-drug\">brentuximab vedotin</ph> and <ph otherprops=\"asparaginase\" outputclass=\"int-drug\">asparaginase</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  brentuximab vedotin  and  asparaginase  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "7",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Asparaginase</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/brentuximab-vedotin-2#bnf_i1557280691044",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/brentuximab-vedotin-2#bnf_i1557280691044_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"brentuximab vedotin\" outputclass=\"int-heading-drug\">brentuximab vedotin</ph> and <ph otherprops=\"axitinib\" outputclass=\"int-drug\">axitinib</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  brentuximab vedotin  and  axitinib  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "8",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Axitinib</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/brentuximab-vedotin-2#bnf_i1557280691045",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/brentuximab-vedotin-2#bnf_i1557280691045_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"brentuximab vedotin\" outputclass=\"int-heading-drug\">brentuximab vedotin</ph> and <ph otherprops=\"azacitidine\" outputclass=\"int-drug\">azacitidine</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  brentuximab vedotin  and  azacitidine  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "9",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Azacitidine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/brentuximab-vedotin-2#bnf_i1557280691046",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/brentuximab-vedotin-2#bnf_i1557280691046_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"brentuximab vedotin\" outputclass=\"int-heading-drug\">brentuximab vedotin</ph> and <ph otherprops=\"azathioprine\" outputclass=\"int-drug\">azathioprine</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  brentuximab vedotin  and  azathioprine  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "10",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Azathioprine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/brentuximab-vedotin-2#bnf_i1557280691047",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/brentuximab-vedotin-2#bnf_i1557280691047_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"Bacillus Calmette-Guérin vaccine\" outputclass=\"int-drug\">Bacillus Calmette-Guérin vaccine</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the risk of generalised infection (possibly life-threatening) when given with</ph> <ph otherprops=\"brentuximab vedotin\" outputclass=\"int-heading-drug\">brentuximab vedotin</ph>. <ph outputclass=\"int-action\">Public Health England advises avoid (refer to Green Book)</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Bacillus Calmette-Guérin vaccine   is predicted to   increase   the risk of generalised infection (possibly life-threatening) when given with   brentuximab vedotin .  Public Health England advises avoid (refer to Green Book) .    \n\n"
						}
					],
					"hasOrder": "11",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Bacillus Calmette-Guérin vaccine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/brentuximab-vedotin-2#bnf_i1557280691048",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/brentuximab-vedotin-2#bnf_i1557280691048_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"brentuximab vedotin\" outputclass=\"int-heading-drug\">brentuximab vedotin</ph> and <ph otherprops=\"balsalazide\" outputclass=\"int-drug\">balsalazide</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  brentuximab vedotin  and  balsalazide  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "12",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Balsalazide</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/brentuximab-vedotin-2#bnf_i1557280691049",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/brentuximab-vedotin-2#bnf_i1557280691049_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"brentuximab vedotin\" outputclass=\"int-heading-drug\">brentuximab vedotin</ph> and <ph otherprops=\"bendamustine\" outputclass=\"int-drug\">bendamustine</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  brentuximab vedotin  and  bendamustine  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "13",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Bendamustine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/brentuximab-vedotin-2#bnf_i1557280691050",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/brentuximab-vedotin-2#bnf_i1557280691050_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"brentuximab vedotin\" outputclass=\"int-heading-drug\">brentuximab vedotin</ph> and <ph otherprops=\"bleomycin\" outputclass=\"int-drug\">bleomycin</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  brentuximab vedotin  and  bleomycin  can increase the risk of myelosuppression. \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/brentuximab-vedotin-2#bnf_i1557280691050_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"brentuximab vedotin\" outputclass=\"int-heading-drug\">Brentuximab vedotin</ph> <ph outputclass=\"int-effect\">increases</ph> <ph outputclass=\"int-parameter\">the risk of pulmonary toxicity when given with</ph> <ph otherprops=\"bleomycin\" outputclass=\"int-drug\">bleomycin</ph>. <ph outputclass=\"int-action\">Manufacturer advises avoid</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Severe",
							"hasOrder": "2",
							"hasTextContent": "Brentuximab vedotin   increases   the risk of pulmonary toxicity when given with   bleomycin .  Manufacturer advises avoid .    \n\n"
						}
					],
					"hasOrder": "14",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Bleomycin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/brentuximab-vedotin-2#bnf_i1557280691051",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/brentuximab-vedotin-2#bnf_i1557280691051_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"brentuximab vedotin\" outputclass=\"int-heading-drug\">brentuximab vedotin</ph> and <ph otherprops=\"bortezomib\" outputclass=\"int-drug\">bortezomib</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  brentuximab vedotin  and  bortezomib  can increase the risk of myelosuppression. \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/brentuximab-vedotin-2#bnf_i1557280691051_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"brentuximab vedotin\" outputclass=\"int-heading-drug\">brentuximab vedotin</ph> and <ph otherprops=\"bortezomib\" outputclass=\"int-drug\">bortezomib</ph> can increase the risk of peripheral neuropathy.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "2",
							"hasTextContent": "Both  brentuximab vedotin  and  bortezomib  can increase the risk of peripheral neuropathy. \n\n"
						}
					],
					"hasOrder": "15",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Bortezomib</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/brentuximab-vedotin-2#bnf_i1557280691052",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/brentuximab-vedotin-2#bnf_i1557280691052_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"brentuximab vedotin\" outputclass=\"int-heading-drug\">brentuximab vedotin</ph> and <ph otherprops=\"bosutinib\" outputclass=\"int-drug\">bosutinib</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  brentuximab vedotin  and  bosutinib  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "16",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Bosutinib</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/brentuximab-vedotin-2#bnf_i1557280691053",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/brentuximab-vedotin-2#bnf_i1557280691053_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"brentuximab vedotin\" outputclass=\"int-heading-drug\">brentuximab vedotin</ph> and <ph otherprops=\"busulfan\" outputclass=\"int-drug\">busulfan</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  brentuximab vedotin  and  busulfan  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "17",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Busulfan</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/brentuximab-vedotin-2#bnf_i1557280691054",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/brentuximab-vedotin-2#bnf_i1557280691054_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"brentuximab vedotin\" outputclass=\"int-heading-drug\">brentuximab vedotin</ph> and <ph otherprops=\"cabazitaxel\" outputclass=\"int-drug\">cabazitaxel</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  brentuximab vedotin  and  cabazitaxel  can increase the risk of myelosuppression. \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/brentuximab-vedotin-2#bnf_i1557280691054_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"brentuximab vedotin\" outputclass=\"int-heading-drug\">brentuximab vedotin</ph> and <ph otherprops=\"cabazitaxel\" outputclass=\"int-drug\">cabazitaxel</ph> can increase the risk of peripheral neuropathy.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "2",
							"hasTextContent": "Both  brentuximab vedotin  and  cabazitaxel  can increase the risk of peripheral neuropathy. \n\n"
						}
					],
					"hasOrder": "18",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Cabazitaxel</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/brentuximab-vedotin-2#bnf_i1557280691055",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/brentuximab-vedotin-2#bnf_i1557280691055_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"brentuximab vedotin\" outputclass=\"int-heading-drug\">brentuximab vedotin</ph> and <ph otherprops=\"cabozantinib\" outputclass=\"int-drug\">cabozantinib</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  brentuximab vedotin  and  cabozantinib  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "19",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Cabozantinib</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/brentuximab-vedotin-2#bnf_i1557280691056",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/brentuximab-vedotin-2#bnf_i1557280691056_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"brentuximab vedotin\" outputclass=\"int-heading-drug\">brentuximab vedotin</ph> and <ph otherprops=\"capecitabine\" outputclass=\"int-drug\">capecitabine</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  brentuximab vedotin  and  capecitabine  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "20",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Capecitabine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/brentuximab-vedotin-2#bnf_i1557280691057",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/brentuximab-vedotin-2#bnf_i1557280691057_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"carbamazepine\" outputclass=\"int-drug\">Carbamazepine</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">decrease</ph> <ph outputclass=\"int-parameter\">the effects of</ph> <ph otherprops=\"brentuximab vedotin\" outputclass=\"int-heading-drug\">brentuximab vedotin</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Carbamazepine   is predicted to   decrease   the effects of   brentuximab vedotin .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "21",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Carbamazepine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/brentuximab-vedotin-2#bnf_i1557280691058",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/brentuximab-vedotin-2#bnf_i1557280691058_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"brentuximab vedotin\" outputclass=\"int-heading-drug\">brentuximab vedotin</ph> and <ph otherprops=\"carbimazole\" outputclass=\"int-drug\">carbimazole</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  brentuximab vedotin  and  carbimazole  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "22",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Carbimazole</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/brentuximab-vedotin-2#bnf_i1557280691059",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/brentuximab-vedotin-2#bnf_i1557280691059_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"brentuximab vedotin\" outputclass=\"int-heading-drug\">brentuximab vedotin</ph> and <ph otherprops=\"carboplatin\" outputclass=\"int-drug\">carboplatin</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  brentuximab vedotin  and  carboplatin  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "23",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Carboplatin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/brentuximab-vedotin-2#bnf_i1557280691060",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/brentuximab-vedotin-2#bnf_i1557280691060_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"brentuximab vedotin\" outputclass=\"int-heading-drug\">brentuximab vedotin</ph> and <ph otherprops=\"carfilzomib\" outputclass=\"int-drug\">carfilzomib</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  brentuximab vedotin  and  carfilzomib  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "24",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Carfilzomib</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/brentuximab-vedotin-2#bnf_i1557280691061",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/brentuximab-vedotin-2#bnf_i1557280691061_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"brentuximab vedotin\" outputclass=\"int-heading-drug\">brentuximab vedotin</ph> and <ph otherprops=\"carmustine\" outputclass=\"int-drug\">carmustine</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  brentuximab vedotin  and  carmustine  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "25",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Carmustine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/brentuximab-vedotin-2#bnf_i1557280691062",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/brentuximab-vedotin-2#bnf_i1557280691062_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"brentuximab vedotin\" outputclass=\"int-heading-drug\">brentuximab vedotin</ph> and <ph otherprops=\"ceritinib\" outputclass=\"int-drug\">ceritinib</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  brentuximab vedotin  and  ceritinib  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "26",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Ceritinib</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/brentuximab-vedotin-2#bnf_i1557280691063",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/brentuximab-vedotin-2#bnf_i1557280691063_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"brentuximab vedotin\" outputclass=\"int-heading-drug\">brentuximab vedotin</ph> and <ph otherprops=\"chlorambucil\" outputclass=\"int-drug\">chlorambucil</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  brentuximab vedotin  and  chlorambucil  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "27",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Chlorambucil</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/brentuximab-vedotin-2#bnf_i1557280691064",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/brentuximab-vedotin-2#bnf_i1557280691064_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"brentuximab vedotin\" outputclass=\"int-heading-drug\">brentuximab vedotin</ph> and <ph otherprops=\"cisplatin\" outputclass=\"int-drug\">cisplatin</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  brentuximab vedotin  and  cisplatin  can increase the risk of myelosuppression. \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/brentuximab-vedotin-2#bnf_i1557280691064_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"brentuximab vedotin\" outputclass=\"int-heading-drug\">brentuximab vedotin</ph> and <ph otherprops=\"cisplatin\" outputclass=\"int-drug\">cisplatin</ph> can increase the risk of peripheral neuropathy.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "2",
							"hasTextContent": "Both  brentuximab vedotin  and  cisplatin  can increase the risk of peripheral neuropathy. \n\n"
						}
					],
					"hasOrder": "28",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Cisplatin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/brentuximab-vedotin-2#bnf_i1557280691065",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/brentuximab-vedotin-2#bnf_i1557280691065_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"brentuximab vedotin\" outputclass=\"int-heading-drug\">brentuximab vedotin</ph> and <ph otherprops=\"cladribine\" outputclass=\"int-drug\">cladribine</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  brentuximab vedotin  and  cladribine  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "29",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Cladribine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/brentuximab-vedotin-2#bnf_i1557280691066",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/brentuximab-vedotin-2#bnf_i1557280691066_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"clarithromycin\" outputclass=\"int-drug\">Clarithromycin</ph> <ph outputclass=\"int-effect\">increases</ph> <ph outputclass=\"int-parameter\">the risk of neutropenia when given with</ph> <ph otherprops=\"brentuximab vedotin\" outputclass=\"int-heading-drug\">brentuximab vedotin</ph>. <ph outputclass=\"int-action\">Manufacturer advises monitor and adjust dose</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Clarithromycin   increases   the risk of neutropenia when given with   brentuximab vedotin .  Manufacturer advises monitor and adjust dose .    \n\n"
						}
					],
					"hasOrder": "30",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Clarithromycin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/brentuximab-vedotin-2#bnf_i1557280691067",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/brentuximab-vedotin-2#bnf_i1557280691067_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"brentuximab vedotin\" outputclass=\"int-heading-drug\">brentuximab vedotin</ph> and <ph otherprops=\"clofarabine\" outputclass=\"int-drug\">clofarabine</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  brentuximab vedotin  and  clofarabine  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "31",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Clofarabine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/brentuximab-vedotin-2#bnf_i1557280691068",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/brentuximab-vedotin-2#bnf_i1557280691068_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"brentuximab vedotin\" outputclass=\"int-heading-drug\">brentuximab vedotin</ph> and <ph otherprops=\"clozapine\" outputclass=\"int-drug\">clozapine</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  brentuximab vedotin  and  clozapine  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "32",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Clozapine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/brentuximab-vedotin-2#bnf_i1557280691069",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/brentuximab-vedotin-2#bnf_i1557280691069_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"brentuximab vedotin\" outputclass=\"int-heading-drug\">brentuximab vedotin</ph> and <ph otherprops=\"co-trimoxazole\" outputclass=\"int-drug\">co-trimoxazole</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  brentuximab vedotin  and  co-trimoxazole  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "33",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Co-trimoxazole</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/brentuximab-vedotin-2#bnf_i1557280691070",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/brentuximab-vedotin-2#bnf_i1557280691070_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"brentuximab vedotin\" outputclass=\"int-heading-drug\">brentuximab vedotin</ph> and <ph otherprops=\"crisantaspase\" outputclass=\"int-drug\">crisantaspase</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  brentuximab vedotin  and  crisantaspase  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "34",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Crisantaspase</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/brentuximab-vedotin-2#bnf_i1557280691071",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/brentuximab-vedotin-2#bnf_i1557280691071_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"brentuximab vedotin\" outputclass=\"int-heading-drug\">brentuximab vedotin</ph> and <ph otherprops=\"crizotinib\" outputclass=\"int-drug\">crizotinib</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  brentuximab vedotin  and  crizotinib  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "35",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Crizotinib</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/brentuximab-vedotin-2#bnf_i1557280691072",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/brentuximab-vedotin-2#bnf_i1557280691072_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"brentuximab vedotin\" outputclass=\"int-heading-drug\">brentuximab vedotin</ph> and <ph otherprops=\"cyclophosphamide\" outputclass=\"int-drug\">cyclophosphamide</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  brentuximab vedotin  and  cyclophosphamide  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "36",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Cyclophosphamide</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/brentuximab-vedotin-2#bnf_i1557280691073",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/brentuximab-vedotin-2#bnf_i1557280691073_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"brentuximab vedotin\" outputclass=\"int-heading-drug\">brentuximab vedotin</ph> and <ph otherprops=\"cytarabine\" outputclass=\"int-drug\">cytarabine</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  brentuximab vedotin  and  cytarabine  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "37",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Cytarabine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/brentuximab-vedotin-2#bnf_i1557280691074",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/brentuximab-vedotin-2#bnf_i1557280691074_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"brentuximab vedotin\" outputclass=\"int-heading-drug\">brentuximab vedotin</ph> and <ph otherprops=\"dabrafenib\" outputclass=\"int-drug\">dabrafenib</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  brentuximab vedotin  and  dabrafenib  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "38",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Dabrafenib</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/brentuximab-vedotin-2#bnf_i1557280691075",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/brentuximab-vedotin-2#bnf_i1557280691075_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"brentuximab vedotin\" outputclass=\"int-heading-drug\">brentuximab vedotin</ph> and <ph otherprops=\"dacarbazine\" outputclass=\"int-drug\">dacarbazine</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  brentuximab vedotin  and  dacarbazine  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "39",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Dacarbazine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/brentuximab-vedotin-2#bnf_i1557280691076",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/brentuximab-vedotin-2#bnf_i1557280691076_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"brentuximab vedotin\" outputclass=\"int-heading-drug\">brentuximab vedotin</ph> and <ph otherprops=\"dactinomycin\" outputclass=\"int-drug\">dactinomycin</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  brentuximab vedotin  and  dactinomycin  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "40",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Dactinomycin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/brentuximab-vedotin-2#bnf_i1557280691077",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/brentuximab-vedotin-2#bnf_i1557280691077_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"brentuximab vedotin\" outputclass=\"int-heading-drug\">brentuximab vedotin</ph> and <ph otherprops=\"dasatinib\" outputclass=\"int-drug\">dasatinib</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  brentuximab vedotin  and  dasatinib  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "41",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Dasatinib</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/brentuximab-vedotin-2#bnf_i1557280691078",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/brentuximab-vedotin-2#bnf_i1557280691078_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"brentuximab vedotin\" outputclass=\"int-heading-drug\">brentuximab vedotin</ph> and <ph otherprops=\"daunorubicin\" outputclass=\"int-drug\">daunorubicin</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  brentuximab vedotin  and  daunorubicin  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "42",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Daunorubicin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/brentuximab-vedotin-2#bnf_i1557280691079",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/brentuximab-vedotin-2#bnf_i1557280691079_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"brentuximab vedotin\" outputclass=\"int-heading-drug\">brentuximab vedotin</ph> and <ph otherprops=\"decitabine\" outputclass=\"int-drug\">decitabine</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  brentuximab vedotin  and  decitabine  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "43",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Decitabine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/brentuximab-vedotin-2#bnf_i1557280691080",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/brentuximab-vedotin-2#bnf_i1557280691080_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"brentuximab vedotin\" outputclass=\"int-heading-drug\">brentuximab vedotin</ph> and <ph otherprops=\"deferiprone\" outputclass=\"int-drug\">deferiprone</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  brentuximab vedotin  and  deferiprone  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "44",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Deferiprone</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/brentuximab-vedotin-2#bnf_i1557280691081",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/brentuximab-vedotin-2#bnf_i1557280691081_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"brentuximab vedotin\" outputclass=\"int-heading-drug\">brentuximab vedotin</ph> and <ph otherprops=\"didanosine\" outputclass=\"int-drug\">didanosine</ph> can increase the risk of peripheral neuropathy.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  brentuximab vedotin  and  didanosine  can increase the risk of peripheral neuropathy. \n\n"
						}
					],
					"hasOrder": "45",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Didanosine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/brentuximab-vedotin-2#bnf_i1557280691082",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/brentuximab-vedotin-2#bnf_i1557280691082_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"brentuximab vedotin\" outputclass=\"int-heading-drug\">brentuximab vedotin</ph> and <ph otherprops=\"disulfiram\" outputclass=\"int-drug\">disulfiram</ph> can increase the risk of peripheral neuropathy.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  brentuximab vedotin  and  disulfiram  can increase the risk of peripheral neuropathy. \n\n"
						}
					],
					"hasOrder": "46",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Disulfiram</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/brentuximab-vedotin-2#bnf_i1557280691083",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/brentuximab-vedotin-2#bnf_i1557280691083_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"brentuximab vedotin\" outputclass=\"int-heading-drug\">brentuximab vedotin</ph> and <ph otherprops=\"docetaxel\" outputclass=\"int-drug\">docetaxel</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  brentuximab vedotin  and  docetaxel  can increase the risk of myelosuppression. \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/brentuximab-vedotin-2#bnf_i1557280691083_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"brentuximab vedotin\" outputclass=\"int-heading-drug\">brentuximab vedotin</ph> and <ph otherprops=\"docetaxel\" outputclass=\"int-drug\">docetaxel</ph> can increase the risk of peripheral neuropathy.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "2",
							"hasTextContent": "Both  brentuximab vedotin  and  docetaxel  can increase the risk of peripheral neuropathy. \n\n"
						}
					],
					"hasOrder": "47",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Docetaxel</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/brentuximab-vedotin-2#bnf_i1557280691084",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/brentuximab-vedotin-2#bnf_i1557280691084_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"brentuximab vedotin\" outputclass=\"int-heading-drug\">brentuximab vedotin</ph> and <ph otherprops=\"doxorubicin\" outputclass=\"int-drug\">doxorubicin</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  brentuximab vedotin  and  doxorubicin  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "48",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Doxorubicin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/brentuximab-vedotin-2#bnf_i1557280691085",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/brentuximab-vedotin-2#bnf_i1557280691085_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"dronedarone\" outputclass=\"int-drug\">Dronedarone</ph> <ph outputclass=\"int-effect\">increases</ph> <ph outputclass=\"int-parameter\">the risk of neutropenia when given with</ph> <ph otherprops=\"brentuximab vedotin\" outputclass=\"int-heading-drug\">brentuximab vedotin</ph>. <ph outputclass=\"int-action\">Manufacturer advises monitor and adjust dose</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Dronedarone   increases   the risk of neutropenia when given with   brentuximab vedotin .  Manufacturer advises monitor and adjust dose .    \n\n"
						}
					],
					"hasOrder": "49",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Dronedarone</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/brentuximab-vedotin-2#bnf_i1557280691086",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/brentuximab-vedotin-2#bnf_i1557280691086_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"brentuximab vedotin\" outputclass=\"int-heading-drug\">brentuximab vedotin</ph> and <ph otherprops=\"epirubicin\" outputclass=\"int-drug\">epirubicin</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  brentuximab vedotin  and  epirubicin  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "50",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Epirubicin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/brentuximab-vedotin-2#bnf_i1557280691087",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/brentuximab-vedotin-2#bnf_i1557280691087_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"brentuximab vedotin\" outputclass=\"int-heading-drug\">brentuximab vedotin</ph> and <ph otherprops=\"eribulin\" outputclass=\"int-drug\">eribulin</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  brentuximab vedotin  and  eribulin  can increase the risk of myelosuppression. \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/brentuximab-vedotin-2#bnf_i1557280691087_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"brentuximab vedotin\" outputclass=\"int-heading-drug\">brentuximab vedotin</ph> and <ph otherprops=\"eribulin\" outputclass=\"int-drug\">eribulin</ph> can increase the risk of peripheral neuropathy.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "2",
							"hasTextContent": "Both  brentuximab vedotin  and  eribulin  can increase the risk of peripheral neuropathy. \n\n"
						}
					],
					"hasOrder": "51",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Eribulin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/brentuximab-vedotin-2#bnf_i1557280691088",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/brentuximab-vedotin-2#bnf_i1557280691088_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"brentuximab vedotin\" outputclass=\"int-heading-drug\">brentuximab vedotin</ph> and <ph otherprops=\"estramustine\" outputclass=\"int-drug\">estramustine</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  brentuximab vedotin  and  estramustine  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "52",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Estramustine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/brentuximab-vedotin-2#bnf_i1557280691089",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/brentuximab-vedotin-2#bnf_i1557280691089_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"brentuximab vedotin\" outputclass=\"int-heading-drug\">brentuximab vedotin</ph> and <ph otherprops=\"ethosuximide\" outputclass=\"int-drug\">ethosuximide</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  brentuximab vedotin  and  ethosuximide  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "53",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Ethosuximide</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/brentuximab-vedotin-2#bnf_i1557280691090",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/brentuximab-vedotin-2#bnf_i1557280691090_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"brentuximab vedotin\" outputclass=\"int-heading-drug\">brentuximab vedotin</ph> and <ph otherprops=\"etoposide\" outputclass=\"int-drug\">etoposide</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  brentuximab vedotin  and  etoposide  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "54",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Etoposide</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/brentuximab-vedotin-2#bnf_i1557280691091",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/brentuximab-vedotin-2#bnf_i1557280691091_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"brentuximab vedotin\" outputclass=\"int-heading-drug\">brentuximab vedotin</ph> and <ph otherprops=\"everolimus\" outputclass=\"int-drug\">everolimus</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  brentuximab vedotin  and  everolimus  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "55",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Everolimus</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/brentuximab-vedotin-2#bnf_i1557280691092",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/brentuximab-vedotin-2#bnf_i1557280691092_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"brentuximab vedotin\" outputclass=\"int-heading-drug\">brentuximab vedotin</ph> and <ph otherprops=\"fludarabine\" outputclass=\"int-drug\">fludarabine</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  brentuximab vedotin  and  fludarabine  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "56",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Fludarabine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/brentuximab-vedotin-2#bnf_i1557280691093",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/brentuximab-vedotin-2#bnf_i1557280691093_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"brentuximab vedotin\" outputclass=\"int-heading-drug\">brentuximab vedotin</ph> and <ph otherprops=\"fluorouracil\" outputclass=\"int-drug\">fluorouracil</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  brentuximab vedotin  and  fluorouracil  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "57",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Fluorouracil</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/brentuximab-vedotin-2#bnf_i1557280691094",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/brentuximab-vedotin-2#bnf_i1557280691094_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"brentuximab vedotin\" outputclass=\"int-heading-drug\">brentuximab vedotin</ph> and <ph otherprops=\"fosphenytoin\" outputclass=\"int-drug\">fosphenytoin</ph> can increase the risk of peripheral neuropathy.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  brentuximab vedotin  and  fosphenytoin  can increase the risk of peripheral neuropathy. \n\n"
						}
					],
					"hasOrder": "58",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Fosphenytoin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/brentuximab-vedotin-2#bnf_i1557280691095",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/brentuximab-vedotin-2#bnf_i1557280691095_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"brentuximab vedotin\" outputclass=\"int-heading-drug\">brentuximab vedotin</ph> and <ph otherprops=\"ganciclovir\" outputclass=\"int-drug\">ganciclovir</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  brentuximab vedotin  and  ganciclovir  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "59",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Ganciclovir</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/brentuximab-vedotin-2#bnf_i1557280691096",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/brentuximab-vedotin-2#bnf_i1557280691096_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"brentuximab vedotin\" outputclass=\"int-heading-drug\">brentuximab vedotin</ph> and <ph otherprops=\"gefitinib\" outputclass=\"int-drug\">gefitinib</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  brentuximab vedotin  and  gefitinib  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "60",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Gefitinib</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/brentuximab-vedotin-2#bnf_i1557280691097",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/brentuximab-vedotin-2#bnf_i1557280691097_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"brentuximab vedotin\" outputclass=\"int-heading-drug\">brentuximab vedotin</ph> and <ph otherprops=\"gemcitabine\" outputclass=\"int-drug\">gemcitabine</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  brentuximab vedotin  and  gemcitabine  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "61",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Gemcitabine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/brentuximab-vedotin-2#bnf_i1557280691098",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/brentuximab-vedotin-2#bnf_i1557280691098_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"brentuximab vedotin\" outputclass=\"int-heading-drug\">brentuximab vedotin</ph> and <ph otherprops=\"hydroxycarbamide\" outputclass=\"int-drug\">hydroxycarbamide</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  brentuximab vedotin  and  hydroxycarbamide  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "62",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Hydroxycarbamide</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/brentuximab-vedotin-2#bnf_i1557280691099",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/brentuximab-vedotin-2#bnf_i1557280691099_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"brentuximab vedotin\" outputclass=\"int-heading-drug\">brentuximab vedotin</ph> and <ph otherprops=\"ibrutinib\" outputclass=\"int-drug\">ibrutinib</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  brentuximab vedotin  and  ibrutinib  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "63",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Ibrutinib</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/brentuximab-vedotin-2#bnf_i1557280691100",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/brentuximab-vedotin-2#bnf_i1557280691100_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"brentuximab vedotin\" outputclass=\"int-heading-drug\">brentuximab vedotin</ph> and <ph otherprops=\"idarubicin\" outputclass=\"int-drug\">idarubicin</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  brentuximab vedotin  and  idarubicin  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "64",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Idarubicin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/brentuximab-vedotin-2#bnf_i1557280691101",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/brentuximab-vedotin-2#bnf_i1557280691101_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"brentuximab vedotin\" outputclass=\"int-heading-drug\">brentuximab vedotin</ph> and <ph otherprops=\"idelalisib\" outputclass=\"int-drug\">idelalisib</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  brentuximab vedotin  and  idelalisib  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "65",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Idelalisib</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/brentuximab-vedotin-2#bnf_i1557280691102",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/brentuximab-vedotin-2#bnf_i1557280691102_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"brentuximab vedotin\" outputclass=\"int-heading-drug\">brentuximab vedotin</ph> and <ph otherprops=\"ifosfamide\" outputclass=\"int-drug\">ifosfamide</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  brentuximab vedotin  and  ifosfamide  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "66",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Ifosfamide</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/brentuximab-vedotin-2#bnf_i1557280691103",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/brentuximab-vedotin-2#bnf_i1557280691103_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"brentuximab vedotin\" outputclass=\"int-heading-drug\">brentuximab vedotin</ph> and <ph otherprops=\"imatinib\" outputclass=\"int-drug\">imatinib</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  brentuximab vedotin  and  imatinib  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "67",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Imatinib</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/brentuximab-vedotin-2#bnf_i1557280691104",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/brentuximab-vedotin-2#bnf_i1557280691104_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"influenza vaccine (live)\" outputclass=\"int-drug\">Influenza vaccine (live)</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the risk of generalised infection (possibly life-threatening) when given with</ph> <ph otherprops=\"brentuximab vedotin\" outputclass=\"int-heading-drug\">brentuximab vedotin</ph>. <ph outputclass=\"int-action\">Public Health England advises avoid (refer to Green Book)</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Influenza vaccine (live)   is predicted to   increase   the risk of generalised infection (possibly life-threatening) when given with   brentuximab vedotin .  Public Health England advises avoid (refer to Green Book) .    \n\n"
						}
					],
					"hasOrder": "68",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Influenza vaccine (live)</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/brentuximab-vedotin-2#bnf_i1557280691105",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/brentuximab-vedotin-2#bnf_i1557280691105_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"brentuximab vedotin\" outputclass=\"int-heading-drug\">brentuximab vedotin</ph> and <ph otherprops=\"interferon alfa\" outputclass=\"int-drug\">interferon alfa</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  brentuximab vedotin  and  interferon alfa  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "69",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Interferon alfa</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/brentuximab-vedotin-2#bnf_i1557280691106",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/brentuximab-vedotin-2#bnf_i1557280691106_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"brentuximab vedotin\" outputclass=\"int-heading-drug\">brentuximab vedotin</ph> and <ph otherprops=\"interferon beta\" outputclass=\"int-drug\">interferon beta</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  brentuximab vedotin  and  interferon beta  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "70",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Interferon beta</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/brentuximab-vedotin-2#bnf_i1557280691107",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/brentuximab-vedotin-2#bnf_i1557280691107_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"brentuximab vedotin\" outputclass=\"int-heading-drug\">brentuximab vedotin</ph> and <ph otherprops=\"irinotecan\" outputclass=\"int-drug\">irinotecan</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  brentuximab vedotin  and  irinotecan  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "71",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Irinotecan</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/brentuximab-vedotin-2#bnf_i1557280691108",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/brentuximab-vedotin-2#bnf_i1557280691108_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"brentuximab vedotin\" outputclass=\"int-heading-drug\">brentuximab vedotin</ph> and <ph otherprops=\"isoniazid\" outputclass=\"int-drug\">isoniazid</ph> can increase the risk of peripheral neuropathy.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  brentuximab vedotin  and  isoniazid  can increase the risk of peripheral neuropathy. \n\n"
						}
					],
					"hasOrder": "72",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Isoniazid</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/brentuximab-vedotin-2#bnf_i1557280691109",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/brentuximab-vedotin-2#bnf_i1557280691109_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"itraconazole\" outputclass=\"int-drug\">Itraconazole</ph> <ph outputclass=\"int-effect\">increases</ph> <ph outputclass=\"int-parameter\">the risk of neutropenia when given with</ph> <ph otherprops=\"brentuximab vedotin\" outputclass=\"int-heading-drug\">brentuximab vedotin</ph>. <ph outputclass=\"int-action\">Manufacturer advises monitor and adjust dose</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Itraconazole   increases   the risk of neutropenia when given with   brentuximab vedotin .  Manufacturer advises monitor and adjust dose .    \n\n"
						}
					],
					"hasOrder": "73",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Itraconazole</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/brentuximab-vedotin-2#bnf_i1557280691110",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/brentuximab-vedotin-2#bnf_i1557280691110_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"ketoconazole\" outputclass=\"int-drug\">Ketoconazole</ph> <ph outputclass=\"int-effect\">increases</ph> <ph outputclass=\"int-parameter\">the risk of neutropenia when given with</ph> <ph otherprops=\"brentuximab vedotin\" outputclass=\"int-heading-drug\">brentuximab vedotin</ph>. <ph outputclass=\"int-action\">Manufacturer advises monitor and adjust dose</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Ketoconazole   increases   the risk of neutropenia when given with   brentuximab vedotin .  Manufacturer advises monitor and adjust dose .    \n\n"
						}
					],
					"hasOrder": "74",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Ketoconazole</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/brentuximab-vedotin-2#bnf_i1557280691111",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/brentuximab-vedotin-2#bnf_i1557280691111_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"brentuximab vedotin\" outputclass=\"int-heading-drug\">brentuximab vedotin</ph> and <ph otherprops=\"lamivudine\" outputclass=\"int-drug\">lamivudine</ph> can increase the risk of peripheral neuropathy.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  brentuximab vedotin  and  lamivudine  can increase the risk of peripheral neuropathy. \n\n"
						}
					],
					"hasOrder": "75",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Lamivudine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/brentuximab-vedotin-2#bnf_i1557280691112",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/brentuximab-vedotin-2#bnf_i1557280691112_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"brentuximab vedotin\" outputclass=\"int-heading-drug\">brentuximab vedotin</ph> and <ph otherprops=\"leflunomide\" outputclass=\"int-drug\">leflunomide</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  brentuximab vedotin  and  leflunomide  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "76",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Leflunomide</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/brentuximab-vedotin-2#bnf_i1557280691113",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/brentuximab-vedotin-2#bnf_i1557280691113_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"brentuximab vedotin\" outputclass=\"int-heading-drug\">brentuximab vedotin</ph> and <ph otherprops=\"lenalidomide\" outputclass=\"int-drug\">lenalidomide</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  brentuximab vedotin  and  lenalidomide  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "77",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Lenalidomide</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/brentuximab-vedotin-2#bnf_i1557280691114",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/brentuximab-vedotin-2#bnf_i1557280691114_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"brentuximab vedotin\" outputclass=\"int-heading-drug\">brentuximab vedotin</ph> and <ph otherprops=\"linezolid\" outputclass=\"int-drug\">linezolid</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  brentuximab vedotin  and  linezolid  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "78",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Linezolid</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/brentuximab-vedotin-2#bnf_i1557280691115",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/brentuximab-vedotin-2#bnf_i1557280691115_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"brentuximab vedotin\" outputclass=\"int-heading-drug\">brentuximab vedotin</ph> and <ph otherprops=\"lomustine\" outputclass=\"int-drug\">lomustine</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  brentuximab vedotin  and  lomustine  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "79",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Lomustine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/brentuximab-vedotin-2#bnf_i1557280691116",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/brentuximab-vedotin-2#bnf_i1557280691116_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"lopinavir\" outputclass=\"int-drug\">Lopinavir</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the risk of neutropenia when given with</ph> <ph otherprops=\"brentuximab vedotin\" outputclass=\"int-heading-drug\">brentuximab vedotin</ph>. <ph outputclass=\"int-action\">Manufacturer advises monitor and adjust dose</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Lopinavir   is predicted to   increase   the risk of neutropenia when given with   brentuximab vedotin .  Manufacturer advises monitor and adjust dose .    \n\n"
						}
					],
					"hasOrder": "80",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Lopinavir</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/brentuximab-vedotin-2#bnf_i1557280691117",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/brentuximab-vedotin-2#bnf_i1557280691117_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"measles, mumps and rubella vaccine, live\" outputclass=\"int-drug\">Measles, mumps and rubella vaccine, live</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the risk of generalised infection (possibly life-threatening) when given with</ph> <ph otherprops=\"brentuximab vedotin\" outputclass=\"int-heading-drug\">brentuximab vedotin</ph>. <ph outputclass=\"int-action\">Public Health England advises avoid (refer to Green Book)</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Measles, mumps and rubella vaccine, live   is predicted to   increase   the risk of generalised infection (possibly life-threatening) when given with   brentuximab vedotin .  Public Health England advises avoid (refer to Green Book) .    \n\n"
						}
					],
					"hasOrder": "81",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Measles, mumps and rubella vaccine, live</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/brentuximab-vedotin-2#bnf_i1557280691118",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/brentuximab-vedotin-2#bnf_i1557280691118_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"brentuximab vedotin\" outputclass=\"int-heading-drug\">brentuximab vedotin</ph> and <ph otherprops=\"melphalan\" outputclass=\"int-drug\">melphalan</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  brentuximab vedotin  and  melphalan  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "82",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Melphalan</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/brentuximab-vedotin-2#bnf_i1557280691119",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/brentuximab-vedotin-2#bnf_i1557280691119_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"brentuximab vedotin\" outputclass=\"int-heading-drug\">brentuximab vedotin</ph> and <ph otherprops=\"mercaptopurine\" outputclass=\"int-drug\">mercaptopurine</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  brentuximab vedotin  and  mercaptopurine  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "83",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Mercaptopurine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/brentuximab-vedotin-2#bnf_i1557280691120",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/brentuximab-vedotin-2#bnf_i1557280691120_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"brentuximab vedotin\" outputclass=\"int-heading-drug\">brentuximab vedotin</ph> and <ph otherprops=\"methotrexate\" outputclass=\"int-drug\">methotrexate</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  brentuximab vedotin  and  methotrexate  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "84",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Methotrexate</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/brentuximab-vedotin-2#bnf_i1557280691121",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/brentuximab-vedotin-2#bnf_i1557280691121_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"brentuximab vedotin\" outputclass=\"int-heading-drug\">brentuximab vedotin</ph> and <ph otherprops=\"metronidazole\" outputclass=\"int-drug\">metronidazole</ph> can increase the risk of peripheral neuropathy.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  brentuximab vedotin  and  metronidazole  can increase the risk of peripheral neuropathy. \n\n"
						}
					],
					"hasOrder": "85",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Metronidazole</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/brentuximab-vedotin-2#bnf_i1557280691122",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/brentuximab-vedotin-2#bnf_i1557280691122_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"brentuximab vedotin\" outputclass=\"int-heading-drug\">brentuximab vedotin</ph> and <ph otherprops=\"mitomycin\" outputclass=\"int-drug\">mitomycin</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  brentuximab vedotin  and  mitomycin  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "86",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Mitomycin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/brentuximab-vedotin-2#bnf_i1557280691123",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/brentuximab-vedotin-2#bnf_i1557280691123_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"brentuximab vedotin\" outputclass=\"int-heading-drug\">brentuximab vedotin</ph> and <ph otherprops=\"mitotane\" outputclass=\"int-drug\">mitotane</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  brentuximab vedotin  and  mitotane  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "87",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Mitotane</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/brentuximab-vedotin-2#bnf_i1557280691124",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/brentuximab-vedotin-2#bnf_i1557280691124_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"brentuximab vedotin\" outputclass=\"int-heading-drug\">brentuximab vedotin</ph> and <ph otherprops=\"mitoxantrone\" outputclass=\"int-drug\">mitoxantrone</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  brentuximab vedotin  and  mitoxantrone  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "88",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Mitoxantrone</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/brentuximab-vedotin-2#bnf_i1557280691125",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/brentuximab-vedotin-2#bnf_i1557280691125_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"brentuximab vedotin\" outputclass=\"int-heading-drug\">brentuximab vedotin</ph> and <ph otherprops=\"mycophenolate\" outputclass=\"int-drug\">mycophenolate</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  brentuximab vedotin  and  mycophenolate  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "89",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Mycophenolate</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/brentuximab-vedotin-2#bnf_i1557280691126",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/brentuximab-vedotin-2#bnf_i1557280691126_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"brentuximab vedotin\" outputclass=\"int-heading-drug\">brentuximab vedotin</ph> and <ph otherprops=\"nelarabine\" outputclass=\"int-drug\">nelarabine</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  brentuximab vedotin  and  nelarabine  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "90",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Nelarabine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/brentuximab-vedotin-2#bnf_i1557280691127",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/brentuximab-vedotin-2#bnf_i1557280691127_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"brentuximab vedotin\" outputclass=\"int-heading-drug\">brentuximab vedotin</ph> and <ph otherprops=\"nilotinib\" outputclass=\"int-drug\">nilotinib</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  brentuximab vedotin  and  nilotinib  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "91",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Nilotinib</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/brentuximab-vedotin-2#bnf_i1557280691128",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/brentuximab-vedotin-2#bnf_i1557280691128_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"brentuximab vedotin\" outputclass=\"int-heading-drug\">brentuximab vedotin</ph> and <ph otherprops=\"nitrofurantoin\" outputclass=\"int-drug\">nitrofurantoin</ph> can increase the risk of peripheral neuropathy.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  brentuximab vedotin  and  nitrofurantoin  can increase the risk of peripheral neuropathy. \n\n"
						}
					],
					"hasOrder": "92",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Nitrofurantoin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/brentuximab-vedotin-2#bnf_i1557280691129",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/brentuximab-vedotin-2#bnf_i1557280691129_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"brentuximab vedotin\" outputclass=\"int-heading-drug\">brentuximab vedotin</ph> and <ph otherprops=\"olanzapine\" outputclass=\"int-drug\">olanzapine</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  brentuximab vedotin  and  olanzapine  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "93",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Olanzapine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/brentuximab-vedotin-2#bnf_i1557280691130",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/brentuximab-vedotin-2#bnf_i1557280691130_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"brentuximab vedotin\" outputclass=\"int-heading-drug\">brentuximab vedotin</ph> and <ph otherprops=\"olaparib\" outputclass=\"int-drug\">olaparib</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  brentuximab vedotin  and  olaparib  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "94",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Olaparib</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/brentuximab-vedotin-2#bnf_i1557280691131",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/brentuximab-vedotin-2#bnf_i1557280691131_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"brentuximab vedotin\" outputclass=\"int-heading-drug\">brentuximab vedotin</ph> and <ph otherprops=\"olsalazine\" outputclass=\"int-drug\">olsalazine</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  brentuximab vedotin  and  olsalazine  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "95",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Olsalazine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/brentuximab-vedotin-2#bnf_i1557280691132",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/brentuximab-vedotin-2#bnf_i1557280691132_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"brentuximab vedotin\" outputclass=\"int-heading-drug\">brentuximab vedotin</ph> and <ph otherprops=\"oxaliplatin\" outputclass=\"int-drug\">oxaliplatin</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  brentuximab vedotin  and  oxaliplatin  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "96",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Oxaliplatin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/brentuximab-vedotin-2#bnf_i1557280691133",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/brentuximab-vedotin-2#bnf_i1557280691133_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"brentuximab vedotin\" outputclass=\"int-heading-drug\">brentuximab vedotin</ph> and <ph otherprops=\"paclitaxel\" outputclass=\"int-drug\">paclitaxel</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  brentuximab vedotin  and  paclitaxel  can increase the risk of myelosuppression. \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/brentuximab-vedotin-2#bnf_i1557280691133_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"brentuximab vedotin\" outputclass=\"int-heading-drug\">brentuximab vedotin</ph> and <ph otherprops=\"paclitaxel\" outputclass=\"int-drug\">paclitaxel</ph> can increase the risk of peripheral neuropathy.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "2",
							"hasTextContent": "Both  brentuximab vedotin  and  paclitaxel  can increase the risk of peripheral neuropathy. \n\n"
						}
					],
					"hasOrder": "97",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Paclitaxel</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/brentuximab-vedotin-2#bnf_i1557280691134",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/brentuximab-vedotin-2#bnf_i1557280691134_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"brentuximab vedotin\" outputclass=\"int-heading-drug\">brentuximab vedotin</ph> and <ph otherprops=\"panobinostat\" outputclass=\"int-drug\">panobinostat</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  brentuximab vedotin  and  panobinostat  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "98",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Panobinostat</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/brentuximab-vedotin-2#bnf_i1557280691135",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/brentuximab-vedotin-2#bnf_i1557280691135_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"brentuximab vedotin\" outputclass=\"int-heading-drug\">brentuximab vedotin</ph> and <ph otherprops=\"pazopanib\" outputclass=\"int-drug\">pazopanib</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  brentuximab vedotin  and  pazopanib  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "99",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Pazopanib</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/brentuximab-vedotin-2#bnf_i1557280691136",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/brentuximab-vedotin-2#bnf_i1557280691136_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"brentuximab vedotin\" outputclass=\"int-heading-drug\">brentuximab vedotin</ph> and <ph otherprops=\"pegaspargase\" outputclass=\"int-drug\">pegaspargase</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  brentuximab vedotin  and  pegaspargase  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "100",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Pegaspargase</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/brentuximab-vedotin-2#bnf_i1557280691137",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/brentuximab-vedotin-2#bnf_i1557280691137_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"brentuximab vedotin\" outputclass=\"int-heading-drug\">brentuximab vedotin</ph> and <ph otherprops=\"peginterferon alfa\" outputclass=\"int-drug\">peginterferon alfa</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  brentuximab vedotin  and  peginterferon alfa  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "101",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Peginterferon alfa</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/brentuximab-vedotin-2#bnf_i1557280691138",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/brentuximab-vedotin-2#bnf_i1557280691138_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"brentuximab vedotin\" outputclass=\"int-heading-drug\">brentuximab vedotin</ph> and <ph otherprops=\"peginterferon beta-1a\" outputclass=\"int-drug\">peginterferon beta-1a</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  brentuximab vedotin  and  peginterferon beta-1a  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "102",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Peginterferon beta-1a</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/brentuximab-vedotin-2#bnf_i1557280691139",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/brentuximab-vedotin-2#bnf_i1557280691139_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"brentuximab vedotin\" outputclass=\"int-heading-drug\">brentuximab vedotin</ph> and <ph otherprops=\"pemetrexed\" outputclass=\"int-drug\">pemetrexed</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  brentuximab vedotin  and  pemetrexed  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "103",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Pemetrexed</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/brentuximab-vedotin-2#bnf_i1557280691140",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/brentuximab-vedotin-2#bnf_i1557280691140_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"brentuximab vedotin\" outputclass=\"int-heading-drug\">brentuximab vedotin</ph> and <ph otherprops=\"pentamidine\" outputclass=\"int-drug\">pentamidine</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  brentuximab vedotin  and  pentamidine  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "104",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Pentamidine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/brentuximab-vedotin-2#bnf_i1557280691141",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/brentuximab-vedotin-2#bnf_i1557280691141_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"brentuximab vedotin\" outputclass=\"int-heading-drug\">brentuximab vedotin</ph> and <ph otherprops=\"pentostatin\" outputclass=\"int-drug\">pentostatin</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  brentuximab vedotin  and  pentostatin  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "105",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Pentostatin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/brentuximab-vedotin-2#bnf_i1557280691142",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/brentuximab-vedotin-2#bnf_i1557280691142_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"brentuximab vedotin\" outputclass=\"int-heading-drug\">brentuximab vedotin</ph> and <ph otherprops=\"phenytoin\" outputclass=\"int-drug\">phenytoin</ph> can increase the risk of peripheral neuropathy.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  brentuximab vedotin  and  phenytoin  can increase the risk of peripheral neuropathy. \n\n"
						}
					],
					"hasOrder": "106",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Phenytoin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/brentuximab-vedotin-2#bnf_i1557280691143",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/brentuximab-vedotin-2#bnf_i1557280691143_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"brentuximab vedotin\" outputclass=\"int-heading-drug\">brentuximab vedotin</ph> and <ph otherprops=\"pixantrone\" outputclass=\"int-drug\">pixantrone</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  brentuximab vedotin  and  pixantrone  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "107",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Pixantrone</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/brentuximab-vedotin-2#bnf_i1557280691144",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/brentuximab-vedotin-2#bnf_i1557280691144_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"brentuximab vedotin\" outputclass=\"int-heading-drug\">brentuximab vedotin</ph> and <ph otherprops=\"pomalidomide\" outputclass=\"int-drug\">pomalidomide</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  brentuximab vedotin  and  pomalidomide  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "108",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Pomalidomide</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/brentuximab-vedotin-2#bnf_i1557280691145",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/brentuximab-vedotin-2#bnf_i1557280691145_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"brentuximab vedotin\" outputclass=\"int-heading-drug\">brentuximab vedotin</ph> and <ph otherprops=\"primaquine\" outputclass=\"int-drug\">primaquine</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  brentuximab vedotin  and  primaquine  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "109",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Primaquine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/brentuximab-vedotin-2#bnf_i1557280691146",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/brentuximab-vedotin-2#bnf_i1557280691146_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"brentuximab vedotin\" outputclass=\"int-heading-drug\">brentuximab vedotin</ph> and <ph otherprops=\"procarbazine\" outputclass=\"int-drug\">procarbazine</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  brentuximab vedotin  and  procarbazine  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "110",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Procarbazine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/brentuximab-vedotin-2#bnf_i1557280691147",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/brentuximab-vedotin-2#bnf_i1557280691147_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"brentuximab vedotin\" outputclass=\"int-heading-drug\">brentuximab vedotin</ph> and <ph otherprops=\"propylthiouracil\" outputclass=\"int-drug\">propylthiouracil</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  brentuximab vedotin  and  propylthiouracil  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "111",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Propylthiouracil</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/brentuximab-vedotin-2#bnf_i1557280691148",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/brentuximab-vedotin-2#bnf_i1557280691148_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"brentuximab vedotin\" outputclass=\"int-heading-drug\">brentuximab vedotin</ph> and <ph otherprops=\"pyrimethamine\" outputclass=\"int-drug\">pyrimethamine</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  brentuximab vedotin  and  pyrimethamine  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "112",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Pyrimethamine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/brentuximab-vedotin-2#bnf_i1557280691149",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/brentuximab-vedotin-2#bnf_i1557280691149_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"brentuximab vedotin\" outputclass=\"int-heading-drug\">brentuximab vedotin</ph> and <ph otherprops=\"raltitrexed\" outputclass=\"int-drug\">raltitrexed</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  brentuximab vedotin  and  raltitrexed  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "113",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Raltitrexed</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/brentuximab-vedotin-2#bnf_i1557280691150",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/brentuximab-vedotin-2#bnf_i1557280691150_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"brentuximab vedotin\" outputclass=\"int-heading-drug\">brentuximab vedotin</ph> and <ph otherprops=\"regorafenib\" outputclass=\"int-drug\">regorafenib</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  brentuximab vedotin  and  regorafenib  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "114",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Regorafenib</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/brentuximab-vedotin-2#bnf_i1557280691151",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/brentuximab-vedotin-2#bnf_i1557280691151_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"rifampicin\" outputclass=\"int-drug\">Rifampicin</ph> <ph outputclass=\"int-effect\">decreases</ph> <ph outputclass=\"int-parameter\">the effects of</ph> <ph otherprops=\"brentuximab vedotin\" outputclass=\"int-heading-drug\">brentuximab vedotin</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Rifampicin   decreases   the effects of   brentuximab vedotin .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "115",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Rifampicin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/brentuximab-vedotin-2#bnf_i1557280691152",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/brentuximab-vedotin-2#bnf_i1557280691152_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"ritonavir\" outputclass=\"int-drug\">Ritonavir</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the risk of neutropenia when given with</ph> <ph otherprops=\"brentuximab vedotin\" outputclass=\"int-heading-drug\">brentuximab vedotin</ph>. <ph outputclass=\"int-action\">Manufacturer advises monitor and adjust dose</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Ritonavir   is predicted to   increase   the risk of neutropenia when given with   brentuximab vedotin .  Manufacturer advises monitor and adjust dose .    \n\n"
						}
					],
					"hasOrder": "116",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Ritonavir</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/brentuximab-vedotin-2#bnf_i1557280691153",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/brentuximab-vedotin-2#bnf_i1557280691153_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"rotavirus vaccine\" outputclass=\"int-drug\">Rotavirus vaccine</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the risk of generalised infection (possibly life-threatening) when given with</ph> <ph otherprops=\"brentuximab vedotin\" outputclass=\"int-heading-drug\">brentuximab vedotin</ph>. <ph outputclass=\"int-action\">Public Health England advises avoid (refer to Green Book)</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Rotavirus vaccine   is predicted to   increase   the risk of generalised infection (possibly life-threatening) when given with   brentuximab vedotin .  Public Health England advises avoid (refer to Green Book) .    \n\n"
						}
					],
					"hasOrder": "117",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Rotavirus vaccine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/brentuximab-vedotin-2#bnf_i1557280691154",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/brentuximab-vedotin-2#bnf_i1557280691154_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"brentuximab vedotin\" outputclass=\"int-heading-drug\">brentuximab vedotin</ph> and <ph otherprops=\"ruxolitinib\" outputclass=\"int-drug\">ruxolitinib</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  brentuximab vedotin  and  ruxolitinib  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "118",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Ruxolitinib</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/brentuximab-vedotin-2#bnf_i1557280691155",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/brentuximab-vedotin-2#bnf_i1557280691155_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"saquinavir\" outputclass=\"int-drug\">Saquinavir</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the risk of neutropenia when given with</ph> <ph otherprops=\"brentuximab vedotin\" outputclass=\"int-heading-drug\">brentuximab vedotin</ph>. <ph outputclass=\"int-action\">Manufacturer advises monitor and adjust dose</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Saquinavir   is predicted to   increase   the risk of neutropenia when given with   brentuximab vedotin .  Manufacturer advises monitor and adjust dose .    \n\n"
						}
					],
					"hasOrder": "119",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Saquinavir</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/brentuximab-vedotin-2#bnf_i1557280691156",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/brentuximab-vedotin-2#bnf_i1557280691156_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"brentuximab vedotin\" outputclass=\"int-heading-drug\">brentuximab vedotin</ph> and <ph otherprops=\"sorafenib\" outputclass=\"int-drug\">sorafenib</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  brentuximab vedotin  and  sorafenib  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "120",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Sorafenib</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/brentuximab-vedotin-2#bnf_i1557280691157",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/brentuximab-vedotin-2#bnf_i1557280691157_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"brentuximab vedotin\" outputclass=\"int-heading-drug\">brentuximab vedotin</ph> and <ph otherprops=\"stavudine\" outputclass=\"int-drug\">stavudine</ph> can increase the risk of peripheral neuropathy.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  brentuximab vedotin  and  stavudine  can increase the risk of peripheral neuropathy. \n\n"
						}
					],
					"hasOrder": "121",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Stavudine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/brentuximab-vedotin-2#bnf_i1557280691158",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/brentuximab-vedotin-2#bnf_i1557280691158_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"brentuximab vedotin\" outputclass=\"int-heading-drug\">brentuximab vedotin</ph> and <ph otherprops=\"sulfadiazine\" outputclass=\"int-drug\">sulfadiazine</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  brentuximab vedotin  and  sulfadiazine  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "122",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Sulfadiazine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/brentuximab-vedotin-2#bnf_i1557280691159",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/brentuximab-vedotin-2#bnf_i1557280691159_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"brentuximab vedotin\" outputclass=\"int-heading-drug\">brentuximab vedotin</ph> and <ph otherprops=\"sulfasalazine\" outputclass=\"int-drug\">sulfasalazine</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  brentuximab vedotin  and  sulfasalazine  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "123",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Sulfasalazine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/brentuximab-vedotin-2#bnf_i1557280691160",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/brentuximab-vedotin-2#bnf_i1557280691160_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"brentuximab vedotin\" outputclass=\"int-heading-drug\">brentuximab vedotin</ph> and <ph otherprops=\"sunitinib\" outputclass=\"int-drug\">sunitinib</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  brentuximab vedotin  and  sunitinib  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "124",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Sunitinib</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/brentuximab-vedotin-2#bnf_i1557280691161",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/brentuximab-vedotin-2#bnf_i1557280691161_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"brentuximab vedotin\" outputclass=\"int-heading-drug\">brentuximab vedotin</ph> and <ph otherprops=\"temozolomide\" outputclass=\"int-drug\">temozolomide</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  brentuximab vedotin  and  temozolomide  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "125",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Temozolomide</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/brentuximab-vedotin-2#bnf_i1557280691162",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/brentuximab-vedotin-2#bnf_i1557280691162_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"brentuximab vedotin\" outputclass=\"int-heading-drug\">brentuximab vedotin</ph> and <ph otherprops=\"temsirolimus\" outputclass=\"int-drug\">temsirolimus</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  brentuximab vedotin  and  temsirolimus  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "126",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Temsirolimus</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/brentuximab-vedotin-2#bnf_i1557280691163",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/brentuximab-vedotin-2#bnf_i1557280691163_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"brentuximab vedotin\" outputclass=\"int-heading-drug\">brentuximab vedotin</ph> and <ph otherprops=\"thalidomide\" outputclass=\"int-drug\">thalidomide</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  brentuximab vedotin  and  thalidomide  can increase the risk of myelosuppression. \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/brentuximab-vedotin-2#bnf_i1557280691163_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"brentuximab vedotin\" outputclass=\"int-heading-drug\">brentuximab vedotin</ph> and <ph otherprops=\"thalidomide\" outputclass=\"int-drug\">thalidomide</ph> can increase the risk of peripheral neuropathy.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "2",
							"hasTextContent": "Both  brentuximab vedotin  and  thalidomide  can increase the risk of peripheral neuropathy. \n\n"
						}
					],
					"hasOrder": "127",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Thalidomide</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/brentuximab-vedotin-2#bnf_i1557280691164",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/brentuximab-vedotin-2#bnf_i1557280691164_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"brentuximab vedotin\" outputclass=\"int-heading-drug\">brentuximab vedotin</ph> and <ph otherprops=\"thiotepa\" outputclass=\"int-drug\">thiotepa</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  brentuximab vedotin  and  thiotepa  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "128",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Thiotepa</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/brentuximab-vedotin-2#bnf_i1557280691165",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/brentuximab-vedotin-2#bnf_i1557280691165_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"brentuximab vedotin\" outputclass=\"int-heading-drug\">brentuximab vedotin</ph> and <ph otherprops=\"tioguanine\" outputclass=\"int-drug\">tioguanine</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  brentuximab vedotin  and  tioguanine  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "129",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Tioguanine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/brentuximab-vedotin-2#bnf_i1557280691166",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/brentuximab-vedotin-2#bnf_i1557280691166_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"brentuximab vedotin\" outputclass=\"int-heading-drug\">brentuximab vedotin</ph> and <ph otherprops=\"topotecan\" outputclass=\"int-drug\">topotecan</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  brentuximab vedotin  and  topotecan  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "130",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Topotecan</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/brentuximab-vedotin-2#bnf_i1557280691167",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/brentuximab-vedotin-2#bnf_i1557280691167_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"brentuximab vedotin\" outputclass=\"int-heading-drug\">brentuximab vedotin</ph> and <ph otherprops=\"trabectedin\" outputclass=\"int-drug\">trabectedin</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  brentuximab vedotin  and  trabectedin  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "131",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Trabectedin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/brentuximab-vedotin-2#bnf_i1557280691168",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/brentuximab-vedotin-2#bnf_i1557280691168_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"brentuximab vedotin\" outputclass=\"int-heading-drug\">brentuximab vedotin</ph> and <ph otherprops=\"treosulfan\" outputclass=\"int-drug\">treosulfan</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  brentuximab vedotin  and  treosulfan  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "132",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Treosulfan</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/brentuximab-vedotin-2#bnf_i1557280691169",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/brentuximab-vedotin-2#bnf_i1557280691169_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"typhoid vaccine, oral\" outputclass=\"int-drug\">Typhoid vaccine, oral</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the risk of generalised infection (possibly life-threatening) when given with</ph> <ph otherprops=\"brentuximab vedotin\" outputclass=\"int-heading-drug\">brentuximab vedotin</ph>. <ph outputclass=\"int-action\">Public Health England advises avoid (refer to Green Book)</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Typhoid vaccine, oral   is predicted to   increase   the risk of generalised infection (possibly life-threatening) when given with   brentuximab vedotin .  Public Health England advises avoid (refer to Green Book) .    \n\n"
						}
					],
					"hasOrder": "133",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Typhoid vaccine, oral</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/brentuximab-vedotin-2#bnf_i1557280691170",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/brentuximab-vedotin-2#bnf_i1557280691170_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"brentuximab vedotin\" outputclass=\"int-heading-drug\">brentuximab vedotin</ph> and <ph otherprops=\"valganciclovir\" outputclass=\"int-drug\">valganciclovir</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  brentuximab vedotin  and  valganciclovir  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "134",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Valganciclovir</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/brentuximab-vedotin-2#bnf_i1557280691171",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/brentuximab-vedotin-2#bnf_i1557280691171_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"varicella-zoster vaccine\" outputclass=\"int-drug\">Varicella-zoster vaccine</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the risk of generalised infection (possibly life-threatening) when given with</ph> <ph otherprops=\"brentuximab vedotin\" outputclass=\"int-heading-drug\">brentuximab vedotin</ph>. <ph outputclass=\"int-action\">Public Health England advises avoid (refer to Green Book)</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Varicella-zoster vaccine   is predicted to   increase   the risk of generalised infection (possibly life-threatening) when given with   brentuximab vedotin .  Public Health England advises avoid (refer to Green Book) .    \n\n"
						}
					],
					"hasOrder": "135",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Varicella-zoster vaccine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/brentuximab-vedotin-2#bnf_i1557280691172",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/brentuximab-vedotin-2#bnf_i1557280691172_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"brentuximab vedotin\" outputclass=\"int-heading-drug\">brentuximab vedotin</ph> and <ph otherprops=\"vinblastine\" outputclass=\"int-drug\">vinblastine</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  brentuximab vedotin  and  vinblastine  can increase the risk of myelosuppression. \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/brentuximab-vedotin-2#bnf_i1557280691172_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"brentuximab vedotin\" outputclass=\"int-heading-drug\">brentuximab vedotin</ph> and <ph otherprops=\"vinblastine\" outputclass=\"int-drug\">vinblastine</ph> can increase the risk of peripheral neuropathy.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "2",
							"hasTextContent": "Both  brentuximab vedotin  and  vinblastine  can increase the risk of peripheral neuropathy. \n\n"
						}
					],
					"hasOrder": "136",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Vinblastine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/brentuximab-vedotin-2#bnf_i1557280691173",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/brentuximab-vedotin-2#bnf_i1557280691173_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"brentuximab vedotin\" outputclass=\"int-heading-drug\">brentuximab vedotin</ph> and <ph otherprops=\"vincristine\" outputclass=\"int-drug\">vincristine</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  brentuximab vedotin  and  vincristine  can increase the risk of myelosuppression. \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/brentuximab-vedotin-2#bnf_i1557280691173_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"brentuximab vedotin\" outputclass=\"int-heading-drug\">brentuximab vedotin</ph> and <ph otherprops=\"vincristine\" outputclass=\"int-drug\">vincristine</ph> can increase the risk of peripheral neuropathy.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "2",
							"hasTextContent": "Both  brentuximab vedotin  and  vincristine  can increase the risk of peripheral neuropathy. \n\n"
						}
					],
					"hasOrder": "137",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Vincristine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/brentuximab-vedotin-2#bnf_i1557280691174",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/brentuximab-vedotin-2#bnf_i1557280691174_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"brentuximab vedotin\" outputclass=\"int-heading-drug\">brentuximab vedotin</ph> and <ph otherprops=\"vindesine\" outputclass=\"int-drug\">vindesine</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  brentuximab vedotin  and  vindesine  can increase the risk of myelosuppression. \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/brentuximab-vedotin-2#bnf_i1557280691174_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"brentuximab vedotin\" outputclass=\"int-heading-drug\">brentuximab vedotin</ph> and <ph otherprops=\"vindesine\" outputclass=\"int-drug\">vindesine</ph> can increase the risk of peripheral neuropathy.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "2",
							"hasTextContent": "Both  brentuximab vedotin  and  vindesine  can increase the risk of peripheral neuropathy. \n\n"
						}
					],
					"hasOrder": "138",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Vindesine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/brentuximab-vedotin-2#bnf_i1557280691175",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/brentuximab-vedotin-2#bnf_i1557280691175_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"brentuximab vedotin\" outputclass=\"int-heading-drug\">brentuximab vedotin</ph> and <ph otherprops=\"vinflunine\" outputclass=\"int-drug\">vinflunine</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  brentuximab vedotin  and  vinflunine  can increase the risk of myelosuppression. \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/brentuximab-vedotin-2#bnf_i1557280691175_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"brentuximab vedotin\" outputclass=\"int-heading-drug\">brentuximab vedotin</ph> and <ph otherprops=\"vinflunine\" outputclass=\"int-drug\">vinflunine</ph> can increase the risk of peripheral neuropathy.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "2",
							"hasTextContent": "Both  brentuximab vedotin  and  vinflunine  can increase the risk of peripheral neuropathy. \n\n"
						}
					],
					"hasOrder": "139",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Vinflunine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/brentuximab-vedotin-2#bnf_i1557280691176",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/brentuximab-vedotin-2#bnf_i1557280691176_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"brentuximab vedotin\" outputclass=\"int-heading-drug\">brentuximab vedotin</ph> and <ph otherprops=\"vinorelbine\" outputclass=\"int-drug\">vinorelbine</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  brentuximab vedotin  and  vinorelbine  can increase the risk of myelosuppression. \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/brentuximab-vedotin-2#bnf_i1557280691176_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"brentuximab vedotin\" outputclass=\"int-heading-drug\">brentuximab vedotin</ph> and <ph otherprops=\"vinorelbine\" outputclass=\"int-drug\">vinorelbine</ph> can increase the risk of peripheral neuropathy.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "2",
							"hasTextContent": "Both  brentuximab vedotin  and  vinorelbine  can increase the risk of peripheral neuropathy. \n\n"
						}
					],
					"hasOrder": "140",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Vinorelbine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/brentuximab-vedotin-2#bnf_i1557280691177",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/brentuximab-vedotin-2#bnf_i1557280691177_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"brentuximab vedotin\" outputclass=\"int-heading-drug\">brentuximab vedotin</ph> and <ph otherprops=\"vismodegib\" outputclass=\"int-drug\">vismodegib</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  brentuximab vedotin  and  vismodegib  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "141",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Vismodegib</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/brentuximab-vedotin-2#bnf_i1557280691178",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/brentuximab-vedotin-2#bnf_i1557280691178_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"yellow fever vaccine, live\" outputclass=\"int-drug\">Yellow fever vaccine, live</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the risk of generalised infection (possibly life-threatening) when given with</ph> <ph otherprops=\"brentuximab vedotin\" outputclass=\"int-heading-drug\">brentuximab vedotin</ph>. <ph outputclass=\"int-action\">Public Health England advises avoid (refer to Green Book)</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Yellow fever vaccine, live   is predicted to   increase   the risk of generalised infection (possibly life-threatening) when given with   brentuximab vedotin .  Public Health England advises avoid (refer to Green Book) .    \n\n"
						}
					],
					"hasOrder": "142",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Yellow fever vaccine, live</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/brentuximab-vedotin-2#bnf_i1557280691179",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/brentuximab-vedotin-2#bnf_i1557280691179_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"brentuximab vedotin\" outputclass=\"int-heading-drug\">brentuximab vedotin</ph> and <ph otherprops=\"zidovudine\" outputclass=\"int-drug\">zidovudine</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  brentuximab vedotin  and  zidovudine  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "143",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Zidovudine</title>"
					}
				}
			],
			"hasSearchLabel": " Brentuximab vedotin  | Interactions",
			"hasSearchLink": {
				"@id": "http://bnf.nice.org.uk/interaction/brentuximab-vedotin-2.html"
			},
			"hasTitle": {
				"@type": "rdf:XMLLiteral",
				"@value": "<title> Brentuximab vedotin </title>"
			},
			"rdfs:label": "brentuximab vedotin"
		}
	]
}